Charles Schwab
INDV icon

Charles Schwab’s Indivior Pharmaceuticals INDV Stock Holding History

Charles Schwab’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.2M Buy
1,224,609
+82,724
+7% +$3M 0.01% 1232
2026
Q1 		$34.8M Sell
1,141,885
-101,708
-8% -$3.36M 0.01% 1409
2025
Q4 		$44.6M Buy
1,243,593
+95,650
+8% +$2.92M 0.01% 1232
2025
Q3 		$27.7M Buy
1,147,943
+840,379
+273% +$17.6M ﹤0.01% 1531
2025
Q2 		$4.53M Buy
+307,564
New +$3.58M ﹤0.01% 2366

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab's INDV Position: Q2 2026 in Review

Charles Schwab increased its Indivior Pharmaceuticals (INDV) stake by 7.2% in Q2 2026, buying an estimated $3M and bringing the position to 1,224,609 shares worth $50.2M. The position accounts for 0.01% of the portfolio, ranked #1232.

Charles Schwab first reported a position in INDV in Q2 2025 and has held it in 5 quarters since. 336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Charles Schwab held 1,224,609 shares of Indivior Pharmaceuticals worth $50.2M as of Q2 2026.
  • Charles Schwab bought 82,724 Indivior Pharmaceuticals shares in Q2 2026, an estimated $3M.
  • Indivior Pharmaceuticals made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1232 holding.
  • Charles Schwab first reported a position in Indivior Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.